DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Nokihara H, Hida T, Kondo M. et al.
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.
J Clin Oncol 2016;
34: abstr 9008
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.